Gender differences in pharmacokinetics of maintenance dosed buprenorphine

Center for Human Toxicology, Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84108, USA.
Drug and alcohol dependence (Impact Factor: 3.28). 04/2011; 118(2-3):479-83. DOI: 10.1016/j.drugalcdep.2011.03.024
Source: PubMed

ABSTRACT Gender differences are known to occur in the pharmacokinetics of many drugs. Mechanisms may include differences in body composition, body weight, cardiac output, hormonal status, and use of different co-medications. Recently subtle gender-dependent differences in cytochrome P450 (CYP) 3A-dependent metabolism have been demonstrated. Buprenorphine N-dealkylation to norbuprenorphine is primarily performed by CYP3A. We therefore asked whether gender-dependent differences occur in the pharmacokinetics of buprenorphine.
A retrospective examination was made of control (buprenorphine/naloxone-only) sessions from a number of drug interaction studies between buprenorphine and antiretroviral drugs. Twenty males and eleven females were identified who had a negative cocaine urine test prior to participation in the control session and were all on the same maintenance dose (16/4 mg) of sublingual buprenorphine/naloxone. Pharmacokinetic data from their control sessions (buprenorphine/naloxone only) were sorted by gender and compared using the two-sample t-test.
Females had significantly higher area under the plasma concentration curve (AUC) and maximum plasma concentrations for buprenorphine, norbuprenorphine and norbuprenorphine-3-glucuronide. AUCs relative to dose per body weight and surface area were significantly higher for only norbuprenorphine. AUCs relative to lean body mass were, however, not significantly different.
Gender-related differences exist in the pharmacokinetics of buprenorphine; differences in body composition appear to have a major impact; differences in CYPA-dependent metabolism may also contribute.

Download full-text


Available from: David E Moody, Jun 16, 2015
1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This paper is the thirty-fifth consecutive installment of the annual review of research concerning the endogenous opioid system. It summarizes papers published during 2012 that studied the behavioral effects of molecular, pharmacological and genetic manipulation of opioid peptides, opioid receptors, opioid agonists and opioid antagonists. The particular topics that continue to be covered include the molecular-biochemical effects and neurochemical localization studies of endogenous opioids and their receptors related to behavior (Section 2), and the roles of these opioid peptides and receptors in pain and analgesia (Section 3); stress and social status (Section 4); tolerance and dependence (Section 5); learning and memory (Section 6); eating and drinking (Section 7); alcohol and drugs of abuse (Section 8); sexual activity and hormones, pregnancy, development and endocrinology (Section 9); mental illness and mood (Section 10); seizures and neurologic disorders (Section 11); electrical-related activity and neurophysiology (Section 12); general activity and locomotion (Section 13); gastrointestinal, renal and hepatic functions (Section 14); cardiovascular responses (Section 15); respiration and thermoregulation (Section 16); and immunological responses (Section 17).
    Peptides 10/2013; 50. DOI:10.1016/j.peptides.2013.10.001 · 2.61 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Opioid maintenance therapy is a well-established first-line treatment approach in opioid dependence. Buprenorphine, a partial opioid agonist, has been found by numerous studies to be an effective and safe medication in the treatment of opioid dependence. At present, buprenorphine is available as a monodrug or in a fixed 4:1 ratio combination with naloxone. A diminished risk of diversion and abuse for the buprenorphine-naloxone combination is likely but not firmly established. Conventional formulations are given sublingually to avoid the hepatic first-pass effect. A novel film tablet is available only in the US and Australia. Other novel, sustained-release formulations (implant, depot) are currently being developed and tested. Recent studies, including a Cochrane meta-analysis, suggest that the retention with buprenorphine is lower than for methadone, but that buprenorphine may be associated with less drug use. Higher doses of buprenorphine are associated with better retention rates. Buprenorphine has a ceiling effect at the opioid receptor with regard to respiratory depression, and may cause fewer fatal intoxications than methadone. Possible antidepressant effects of buprenorphine and its use in comorbid psychiatric patients has not been studied in much detail. Clinical implications are discussed.
    01/2015; 6:1-14. DOI:10.2147/SAR.S45585
  • [Show abstract] [Hide abstract]
    ABSTRACT: Preliminary evidence suggests there is minimal withdrawal following cessation of chronically administered buprenorphine and that opioid withdrawal symptoms are delayed compared to other opioids. The present study compared the time course and magnitude of buprenorphine withdrawal versus a prototypical mu opioid agonist, morphine. Healthy, out-of-treatment opioid dependent residential volunteers (N=7) were stabilized either on intramuscular buprenorphine (32 mg/day) or morphine (120 mg/day) administered in four divided doses for nine days. They then underwent an 18-day period of spontaneous withdrawal during which four double-blind IM placebo injections were administered daily. Stabilization and spontaneous withdrawal were assessed for the second opioid using the same time course. Opioid withdrawal measures were collected eight times daily. Morphine withdrawal was significantly (p<0.05) greater than buprenorphine withdrawal as measured by mean peak ratings of: clinical opiate withdrawal scale (COWS); subjective opiate withdrawal scale (SOWS); all subscales of the Profile of Mood States (POMS); sick and pain (0-100) visual analog scales; systolic and diastolic blood pressure; heart rate; respiratory rate; and pupil dilation. Peak ratings on COWS and SOWS occurred on day two of morphine withdrawal and were significantly greater than day two of buprenorphine withdrawal. Subjective reports of morphine withdrawal resolved on average by day seven. There was minimal evidence of buprenorphine withdrawal on any measure. In conclusion, spontaneous withdrawal from high-dose buprenorphine appears subjectively and objectively milder as compared to morphine for at least 18 days after drug cessation.
    Journal of Pharmacology and Experimental Therapeutics 11/2013; 348(2). DOI:10.1124/jpet.113.209478 · 3.86 Impact Factor